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the Frontal Systems Behavior Scale- FrSBE) and psychological 
measures (e.g. mood, purpose in life, illness perceptions, spirituality) 
were obtained. We followed patients up at 3-monthly intervals to 
monitor whether they had accepted / refused NIV or gastrostomy. 
After intervention decisions, further interviews repeated baseline 
measures and assessed further intervention-specific beliefs. 
Results: We observed higher premorbid IQ and educational level 
and an active approach towards illness in those making a decision to 
refuse/accept an intervention. Aspects of executive dysfunction rated 
on the FrSBe at baseline and post decision appeared related to 
intervention refusal. Also relevant were patients' own concerns, 
understanding of and perceived necessity for an intervention, as well 
as aspects of spirituality. 
Conclusions: Since other studies have demonstrated the relevance 
of executive dysfunction for treatment compliance and prognosis in 
ALS, current findings raise the possibility that cognitive impairment in 
people with ALS may be also be influential in how interventions are 
made available or information is presented to patients. Greater 
awareness needs to be raised of these non-illness related factors 
that may influence decision-making and therefore survival. 
 
Understanding the goal-setting process in cognitive 
rehabilitation for people with early-stage dementia  
Aleksandra Kudlicka, Suzannah Evans, Linda Clare 
Objective: There is promising evidence that people with early-stage 
dementia (PwD) can benefit from individualised cognitive 
rehabilitation interventions, and can successfully engage in the 
process of eliciting therapeutic goals. The Bangor Goal Setting 
Interview schedule was developed as a means of structuring the 
process of identifying therapy goals. In this study we examined the 
goal-setting process and the nature of the goals identified. 
Participants and methods: The Bangor Goal Setting Interview was 
used to elicit therapy goals for people with early stage AD, vascular, 
or mixed dementia as part of the baseline assessment in the ongoing 
GREAT trial. Researchers and PwD worked together to identify two 
or three specific, measurable, achievable, personally relevant and 
time-bound therapy objectives related to everyday functioning. 
Thematic analysis was used to reveal common themes in the 
identified goals.  
Results: We analysed a total of 591 therapy goals identified by 209 
PwD. Goals were associated with nine domains: socialising, 
exercising, engaging in meaningful activities, using new technology, 
carrying out activities of daily living, remembering names, locating 
lost items, managing medication and improving orientation. 
Participants were motivated to work on these goals for a range of 
reasons, including reducing dependence and improving enjoyment of 
life.  
Conclusions: Significant numbers of people with early stage 
dementia are able to identify meaningful therapy objectives. These 
personalised rehabilitation goals provide information about the areas 
where support would be most welcomed by people with dementia, 
and can be used to inform the development of genuinely person-
centred rehabilitation interventions. 
 
Developing a cognitive rehabilitation approach for people with 
Parkinson's Disease Dementia and Dementia with Lewy Bodies: 
the CORD-PD trial  
Tamlyn Watermeyer, Julie Roberts, Linda Clare, John Hindle  
Objective: Approximately 30% of people with Parkinson's disease 
(PD) experience a dementia that shares a similar neuropsychological 
profile to that of Dementia with Lewy Bodies (DLB). Pharmacological 
treatments are available, but due to possible side-effects, may not be 
suitable for all patients. Non-pharmacological interventions may offer 
an alternative to support people with early Parkinson's disease 
dementia (PDD) and DLB. Cognition-focused interventions, mostly 
cognitive training, have been explored in people with PD who have 
mild cognitive impairment, but no studies to date have assessed 
such interventions in PDD or DLB. The efficacy of cognitive 
rehabilitation (CR) in Alzheimer's disease and other dementias is 
currently being explored in the ongoing GREAT trial. However, since 
the application of CR in PDD and DLB may be complicated by the 
distinct features of these disorders, notably their parkinsonian 
symptoms, these patients were not included in GREAT. Our objective 
was to adapt the CR approach for people with PDD and DLB. 
Participants and methods: CORD-PD is an ongoing pilot RCT that 
aims to assess the feasibility and potential effectiveness of CR for 
people with early PDD and DLB.  
Results: We will make use of case studies from our work so far to 
illustrate the types of goals identified. Issues surrounding goal-setting 
and implementing CR with PDD and DLB patients will be discussed.  
Conclusions: We will consider the expected results and possible 
clinical implications of this research. Finally, we will reflect upon the 
lessons learned from this pilot study for the development of a future 
fully powered RCT. 
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The scientific and clinical relevance of studying rare 
genetic/neurodevelopmental disease  
Tjitske Kleefstra, Rolf Pfundt, Han Brunner, Jos Egger  
Objective: Intellectual disability (ID) with or without autism spectrum 
disorders (ASD), is one of the main reasons for referral to a clinical 
geneticist. ID has a major impact on affected individuals, their 
families and society. The recent advances in genetic technologies 
have enabled to identify disease causing variants throughout the 
whole human exome, even at the single base-pair level of the DNA. 
This significant increase in diagnostic potential is of high value for 
proper genetic counseling and paves the way for studying 
fundamental aspects of brain functioning on one hand and the more 
personalized approach of syndrome specific management of ID 
disorders at the clinical site on the other hand. 
Participants and Methods: So far, over 2000 ID patients have been 
investigated in our genome diagnostic center by whole exome 
sequencing which revealed a diagnostic yield of around 30%. 
Though most genes are very rarely affected, by collaborative efforts 
with other (inter)national genetic departments, substantial cohorts 
enable the definition of numerous such novel rare genetic 
syndromes. 
Results: Examples of novel syndromes that we have recently 
defined are GATAD2B, POGZ, KBG, USP9X and DDX3X. The 
increase in novel syndromes needs multidisciplinary expertise and 
care including neuropsychiatric involvement. 
Conclusions: The potential of novel genetic techniques will be 
discussed and examples of novel syndromes will be given. 
Syndrome specific management and how to centralize expert 
knowledge will be highlighted by our experience through our expert 
center and the formation of European Reference Networks. 
 
Phelan-McDermid syndrome: Neuropsychological phenotype, 
cerebellar functioning and treatment selection  
Jos Egger, Willem Verhoeven, Renée Zwanenburg, Conny Van 
Ravenswaaij, Clara Bonaglia, Tjitske Kleefstra 
Objective: The 22q13.3 deletion syndrome or Phelan-McDermid 
syndrome is characterized by a variable degree of intellectual 
disability, impaired speech and language as well as social 
communicative skills, and mild dysmorphic features. The SHANK3 
gene is thought to be a major contributor to the phenotype. Apart 
from the syndrome associated autistic features, symptoms from the 
bipolar spectrum can be discerned, in particular behaviour instability 
and fluctuating mood culminating in a (hypo)manic state. In case of 
coincident major somatic events, a deteriorating course may occur. 
Participants and Methods: The present study comprises seven 
adult patients (four females, three males; aged 21-44 years) with 
genetically proven Phelan-McDermid syndrome. Data from medical 
records were collected and extensive assessment of 
neuropsychological variables was performed to identify cognitive 
characteristics and their relation with psychopathology and treatment. 
Results: All patients showed profound communication deficits and 
their developmental functioning ranged from 1;0 to 6;3 years. In 
addition, they had slow speed of information processing, impairment 
of attentional and executive functions, and cognitive alexithymia. As 
to psychopathology, features from the affective and anxiety domains 
were prominent findings in these seven patients suggesting the 
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